38 related articles for article (PubMed ID: 11770980)
21. Clinical applications of N-acetylcysteine.
Kelly GS
Altern Med Rev; 1998 Apr; 3(2):114-27. PubMed ID: 9577247
[TBL] [Abstract][Full Text] [Related]
22. N-acetylcysteine use for amelioration of aminoglycoside-induced ototoxicity in dialysis patients.
Feldman L; Sherman RA; Weissgarten J
Semin Dial; 2012; 25(5):491-4. PubMed ID: 22708712
[TBL] [Abstract][Full Text] [Related]
23. Use of N-acetylcysteine in the management of coronary artery diseases.
Marchetti G; Lodola E; Licciardello L; Colombo A
Cardiologia; 1999 Jul; 44(7):633-7. PubMed ID: 10476588
[TBL] [Abstract][Full Text] [Related]
24. Managing patients with acute myocardial ischemia and reperfusion injury with N-acetylcysteine.
Stewart S; Ryan C; Poropat S
Dimens Crit Care Nurs; 1997; 16(3):122-31. PubMed ID: 9188292
[TBL] [Abstract][Full Text] [Related]
25. How to protect from contrast media-induced nephropathy?
Scheller B
Clin Res Cardiol; 2007 Mar; 96(3):125-9. PubMed ID: 17294353
[No Abstract] [Full Text] [Related]
26. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals.
Asevedo E; Cunha GR; Zugman A; Mansur RB; Brietzke E
Rev Neurosci; 2012; 23(4):353-62. PubMed ID: 22944654
[TBL] [Abstract][Full Text] [Related]
27. Acetylcysteine for radiocontrast nephropathy.
Tepel M; Zidek W
Curr Opin Crit Care; 2001 Dec; 7(6):390-2. PubMed ID: 11805540
[TBL] [Abstract][Full Text] [Related]
28. N-acetylcysteine in the prevention of contrast-induced nephropathy.
Fishbane S
Clin J Am Soc Nephrol; 2008 Jan; 3(1):281-7. PubMed ID: 18003766
[TBL] [Abstract][Full Text] [Related]
29. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure.
Sklar GE; Subramaniam M
Ann Pharmacother; 2004 Mar; 38(3):498-500. PubMed ID: 14742832
[TBL] [Abstract][Full Text] [Related]
30. L-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline.
McCaddon A; Hudson PR
CNS Spectr; 2010 Jan; 15(1 Suppl 1):2-5; discussion 6. PubMed ID: 20397369
[TBL] [Abstract][Full Text] [Related]
31. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
Walker PD; Brokering KL; Theobald JC
Pharmacotherapy; 2003 Dec; 23(12):1617-26. PubMed ID: 14695041
[TBL] [Abstract][Full Text] [Related]
32. [Value of N-acetylcysteine to prevent nephrotoxicity from iodinated contrast agents].
Deray G
J Radiol; 2004 Jun; 85(6 Pt 1):725-7. PubMed ID: 15243372
[TBL] [Abstract][Full Text] [Related]
33. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease.
Dekhuijzen PN
Eur Respir J; 2004 Apr; 23(4):629-36. PubMed ID: 15083766
[TBL] [Abstract][Full Text] [Related]
34. N-acetylcysteine for cholesteatoma?
Altschuler EL
J Otolaryngol; 2001 Feb; 30(1):67. PubMed ID: 11770980
[No Abstract] [Full Text] [Related]
35. N-acetylcysteine administration in the critically ill.
Walsh TS; Lee A
Intensive Care Med; 1999 May; 25(5):432-4. PubMed ID: 10401934
[No Abstract] [Full Text] [Related]
36. [N-Acetylcysteine: new possibilities to use an old substance].
Ahola T; Lapatto R
Duodecim; 1999; 115(4):375-9. PubMed ID: 11830885
[No Abstract] [Full Text] [Related]
37. Paracetamol poisoning: the action line and the timing of acetylcysteine therapy.
Delanty N; Fitzgerald DJ
Ir Med J; 1996; 89(5):156, 158. PubMed ID: 8936831
[No Abstract] [Full Text] [Related]
38. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
